ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2897

The Risk Of Deep Vein Thrombosis and Pulmonary Embolism In Systemic Lupus Erythematosus: A Population-Based Cohort Study

J. Antonio Avina-Zubieta1, Eric C. Sayre2, Diane Lacaille1,3 and John M. Esdaile4, 1Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, 2Arthritis Research Centre of Canada, Richmond, BC, Canada, 3Medicine, University of British Columbia, Vancouver, BC, Canada, 4Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Lupus, population studies, pulmonary complications and risk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects: Cardiovascular and Other Complications of Lupus

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Previous hospital-based studies have shown that patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease, but limited population-based data are available on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE). We estimated the population-based risk of newly recorded DVT and PE among incident cases with SLE compared to controls from the general population using physician-billing and hospitalization databases that cover the entire population of the province of British Columbia, Canada (~ 5 million).

Patients and Methods:

Our data include all visits to health professionals and all hospital admissions from Jan 1, 1990 to Dec 31, 2010 and all dispensed medications from Sept 1, 1995 to Dec 31, 2010 for all individuals. We conducted a retrospective matched cohort study among patients satisfying at least one of the following criteria: a) diagnosis of SLE in adults on at least two visits within a two-year period between Jan 1996 and Dec 2010 by a non-rheumatologist physician; b) diagnosis of SLE on at least one visit by a rheumatologist or from hospitalization. To increase specificity we excluded cases that were not confirmed by a rheumatologist if they were seen at a later point. Ten non-SLE controls matched by birth year, sex and calendar year of follow-up were selected from the general population for each case. Outcomes: incident PE, DVT, and PE or DVT events based on hospitalization records (for PE and DVT), outpatient visits (DVT) or death certificates (all outcomes). For non-fatal outcomes, we also required the use of anticoagulant medication within six-months of the event as part of all outcome definitions. We estimated relative risks (RRs) comparing SLE with age-, sex- and entry time-matched comparison cohorts, adjusting for potential cardiovascular risk factors.

Results:

Among 5,031 incident SLE cases, 72, 72 and 121 developed a first time DVT, PE, and PE or DVT event, respectively (incidence rates = 3.4, 3.4 and 5.8 per 1,000 person years, respectively) (see table). Compared with the age, sex, and entry-time-matched controls, the RRs were 5.2 (95% CI; 3.8 – 6.9), 4.6 (95% CI; 3.5 – 6.2) and 4.8 (95% CI; 3.8 – 6.0) for DVT, PE, and DVT or PE, respectively. After adjusting for covariates the results remained similar (see table). The risk of developing DVT, PE or either event was highest within the first year following diagnosis of SLE, decreasing over time and persisting after 5 years.

Conclusion:

This large population-based study indicates an increased risk of DVT and PE in patients with SLE. Our results support the need for increase monitoring for these complications in SLE patients, especially within the first year of disease onset.

Table: Risk of Incident PE, DVT or DVT or PE according to SLE Status

 

SLE

n = 5,031

Non-SLE

n = 50,310

Incidence Rate Ratios of DVT

DVT events, N

72

136

Incidence Rate/1000 Person-Years

3.4

0.7

Age-,sex-, and entry time-matched RRs (95% CI)

5.2 (3.8 – 6.9)

1.0

  < 1 year of disease duration

8.6 (4.9 – 15.1)

1.0

  1- 4.9 years of disease duration

4.7 (2.9 – 7.4)

1.0

  5+ years of disease duration

3.4 (1.8 – 6.2)

1.0

Multivariable RR (95% CI)

3.9 (2.8 – 5.6)

1.0

Females

4.0 (2.7 – 5.9)

1.0

Males

4.0 (1.8 – 9.1)

1.0

Incidence Rate Ratios of PE

PE events, N

72

150

Incidence Rate/1000 Person-Years

3.4

0.7

Age-,sex-, and entry time-matched RRs (95% CI)

4.6 (3.5 – 6.2)

1.0

  < 1 year of disease duration

14.9 (8.4 – 26.8)

1.0

  1- 4.9 years of disease duration

3.4 (2.1 – 5.4)

1.0

  5+ years of disease duration

2.2 (1.1 – 4.2)

1.0

Multivariable RR

3.5 (2.5 – 4.8)

1.0

Females

3.4 (2.3 – 4.9)

1.0

Males

3.9 (1.6 – 9.4)

1.0

Incidence Rate Ratios of DVT or PE

DVT and PE events, N

121

247

Incidence Rate/1000 Person-Years

5.8

1.2

Age-,sex-, and entry time-matched RRs (95% CI)

4.8 (3.8 – 6.0)

1.0

  < 1 year of disease duration

11.8 (7.8 – 17.8)

1.0

  1- 4.9 years of disease duration

3.9 (2.7 – 5.5)

1.0

  5+ years of disease duration

2.3 (1.4 – 3.9)

1.0

Multivariable RR

3.6 (2.8 – 4.7)

1.0

Females

3.6 (2.7 – 4.8)

1.0

Males

3.6 (1.9 – 7.0)

1.0


Disclosure:

J. A. Avina-Zubieta,
None;

E. C. Sayre,
None;

D. Lacaille,
None;

J. M. Esdaile,

Shoppers Drug Mart,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-risk-of-deep-vein-thrombosis-and-pulmonary-embolism-in-systemic-lupus-erythematosus-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology